Journal of Aerosol Medicine and Pulmonary Drug Delivery
Scope & Guideline
Connecting research and practice in aerosol medicine.
Introduction
Aims and Scopes
- Aerosol Drug Delivery Systems:
Research in this area includes the development and optimization of various aerosol drug delivery devices, such as metered-dose inhalers (MDIs), nebulizers, and dry powder inhalers (DPIs). Studies often focus on how device characteristics influence drug delivery efficiency and patient outcomes. - Pharmacokinetics and Pharmacodynamics of Inhaled Medications:
This includes investigations into the absorption, distribution, metabolism, and excretion of inhaled drugs. Understanding the pharmacokinetic profiles of medications delivered via aerosols is crucial for optimizing dosing regimens and therapeutic efficacy. - Innovative Formulation Development:
Research on novel formulations, including liposomal, nanoparticle, and polymer-based systems, aims to enhance the stability, solubility, and delivery of active pharmaceutical ingredients (APIs) through inhalation. - Clinical Outcomes and Patient-Centric Studies:
The journal emphasizes studies that evaluate the clinical effectiveness of aerosol therapies in real-world settings, focusing on patient adherence, usability of inhalation devices, and overall treatment outcomes. - In Vitro and In Vivo Models:
A significant portion of research employs advanced in vitro and in vivo models to simulate respiratory conditions and assess aerosol deposition, drug efficacy, and safety profiles.
Trending and Emerging
- Nanoparticle and Nanotechnology Applications:
Increasing interest in the use of nanoparticles for drug delivery, particularly for targeting lung diseases such as tuberculosis and cancer, highlights a shift toward more sophisticated and effective inhalation therapies. - Personalized Medicine Approaches:
Research into personalized inhalation therapies that consider individual patient characteristics and preferences is gaining traction, indicating a move towards more tailored therapeutic strategies. - Impact of E-Cigarettes and Vaping on Respiratory Health:
With the rise in vaping, studies examining the effects of e-cigarette aerosols on respiratory function and health outcomes are becoming more prevalent, reflecting public health concerns. - Advanced In Vitro Models for Drug Testing:
The development of sophisticated in vitro systems that mimic human respiratory conditions for drug testing is emerging as a critical area of research, enhancing the predictive value of preclinical studies. - Sustainability in Aerosol Delivery Devices:
There is a growing focus on developing environmentally sustainable inhaler technologies, particularly in response to regulatory pressures and public demand for greener pharmaceutical practices.
Declining or Waning
- Traditional Nebulization Techniques:
Research on conventional nebulizer systems appears to be declining as newer technologies, such as vibrating mesh nebulizers and soft mist inhalers, gain popularity for their efficiency and patient convenience. - Non-Inhalation Drug Delivery Methods:
There is a noticeable decrease in studies focusing on non-inhalation methods of drug delivery within the context of aerosol medicine, as the field shifts towards optimizing inhaled therapies specifically. - Basic Aerosol Science without Clinical Application:
While foundational aerosol science remains relevant, there seems to be a waning interest in purely theoretical studies that do not directly contribute to clinical applications or improvements in patient care. - Pharmacokinetics of Non-Respiratory Drugs:
Research focused on the pharmacokinetics of drugs not intended for respiratory diseases has diminished, as the journal's emphasis shifts towards inhaled therapies specifically tailored for respiratory conditions.
Similar Journals
Expert Opinion on Drug Delivery
Navigating the Future of Drug Delivery Through Expert AnalysisExpert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.
Drug Delivery and Translational Research
Innovating Today for Healthier Tomorrows.Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.
Journal of Pharmacy & Pharmacognosy Research
Empowering Research in Pharmaceutical SciencesJournal of Pharmacy & Pharmacognosy Research, published by JOURNAL PHARMACY & PHARMACOGNOSY RESEARCH-JPPRES, is a prominent open-access journal established in 2013, headquartered in Antofagasta, Chile. With a focus on the fields of Complementary and Alternative Medicine, Drug Discovery, Pharmaceutical Science, Pharmacology, and Pharmacy, this journal is recognized for its commitment to advancing research and disseminating knowledge within these important areas. With a current impact factor that reflects its academic rigor and relevance, the journal has achieved substantial recognition, evident by its Q2 and Q3 quartile rankings in multiple categories, indicating its growing influence on the scientific community. The Scopus rankings further highlight its standing in pharmacy and pharmacological disciplines, providing a valuable platform for researchers, professionals, and students to share their findings and insights. With its open access model, the journal ensures that high-quality research is available to a global audience, paving the way for collaborative advancements in pharmaceutical sciences.
Pharmaceutical Sciences
Empowering global health through cutting-edge pharmaceutical research.Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.
Pakistan Journal of Pharmaceutical Sciences
Bridging academia and industry through pharmaceutical insights.Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Exploring therapeutic frontiers for eye diseases.JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.
JOURNAL OF PHARMACEUTICAL SCIENCES
Elevating research standards in the realm of pharmaceutics.The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.
International Journal of Pharmacology
Exploring the Depths of Drug Actions and InteractionsWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
Advanced Pharmaceutical Bulletin
Catalyzing Collaboration in Cutting-edge Pharmaceutical ResearchAdvanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.
CURRENT DRUG TARGETS
Elevating Drug Discovery to New HeightsCURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.